

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/766,106	10/766,106 01/27/2004		Danny Lewis	PRJ-006CN	2190
959	7590	12/05/2006		EXAMINER	
		FIELD, LLP	AZPURU, CARLOS A		
ONE POST BOSTON,				ART UNIT	PAPER NUMBER
				1615	
				DATE MAILED: 12/05/2006	6

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/766,106	LEWIS ET AL.	
Examiner	Art Unit	
Carlos A. Azpuru	1615	

•								
	Carlos A. Azpuru	1615						
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress					
THE REPLY FILED <u>16 November 2006</u> FAILS TO PLACE THI								
<ol> <li>The reply was filed after a final rejection, but prior to or o this application, applicant must timely file one of the folloplaces the application in condition for allowance; (2) a No. (3) a Request for Continued Examination (RCE) in comp following time periods:</li> </ol>	n the same day as filing a Notice o wing replies: (1) an amendment, a ptice of Appeal (with appeal fee) in	f Appeal. To avoid ab ffidavit, or other evide compliance with 37 (	ence, which CFR 41.31; or					
a) The period for reply expires 5 months from the mailing date of	the final rejection.							
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.  Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO								
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).								
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened stabove, if checked. Any reply received by the Office later than three month earned patent term adjustment. See 37 CFR 1.704(b).  NOTICE OF APPEAL	and the corresponding amount of the fee, attory period for reply originally set in the	The appropriate extension final Office action: or (2)	n fee under 37 as set forth in (b)					
2. The Notice of Appeal was filed on A brief in com	pliance with 37 CFR 41 37 must be	filed within two mon	the of the date					
of filing the Notice of Appeal (37 CFR 41.37(a)), or any e Since a Notice of Appeal has been filed, any reply must be AMENDMENTS	xtension thereof (37 CFR 41.37(e))	), to avoid dismissal d	of the appeal.					
3. The proposed amendment(s) filed after a final rejection.	but prior to the date of filing a brief	f will not be entered l	necause					
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because  (a) They raise new issues that would require further consideration and/or search (see NOTE below);								
(b) ☐ They raise the issue of new matter (see NOTE belo (c) ☐ They are not deemed to place the application in be		educing or simplifying	the issues for					
appeal; and/or (d)☐ They present additional claims without canceling a	corresponding number of finally re	jected claims.						
NOTE: See Continuation Sheet. (See 37 CFR 1.1	16 and 41.33(a)).							
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).								
5. Applicant's reply has overcome the following rejection(s): 112, first paragraph for written description. 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling								
the non-allowable claim(s).	mowable ii subfilitted in a separate,	, umery nied amendm	ent canceling					
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows:	☑ will not be entered, or b) ☐ w vided below or appended.	ill be entered and an	explanation of					
Claim(s) allowed:			•					
Claim(s) objected to: 12-20.								
Claim(s) rejected: <u>1-11,21 and 22</u> .								
Claim(s) withdrawn from consideration:								
AFFIDAVIT OR OTHER EVIDENCE	•							
B.  The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an and was not earlier presented. See 37 CFR 1.116(e).	d sufficient reasons why the affida	vit or other evidence i	s necessary					
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to of showing a good and sufficient reasons why it is necessar	vercome all rejections under appea	al and/or appellant fa	ils to provide a					
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	entry is below or attac	hed.					
11.   The request for reconsideration has been considered but	t does NOT place the application is	n condition for allows	nce hecause.					
·		reordiner allowa	Alce because.					
<ul><li>12.  Note the attached Information Disclosure Statement(s).</li><li>13.  Other:</li></ul>	(P10/SB/U8) Paper No(s).		//					
	1	chility	'n-					
		Primary Examiner						
		Art Unit: 1615	1					

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Advisory Action Before the Filing of an Appeal Brief

Part of Paper No. 20061203

Continuation of 3. NOTE: The new claims introduce new terms such as "therapeutic genes" ansd "small bioactive molecules" which are not defined in the specification. It is further noted that the Markush Group of bioactives in claim 23 does not include insulin.. Lastly, which interferon is contemplated by new claim 24?.